Pharmaceutical

Transgene’s stock drops after Phase II cancer jab trial misses primary endpoint

Despite this setback, Transgene plans to explore the potential benefits of the vaccine in specific patient populations.

Oct 16, 2024 - 04:00
Transgene’s stock drops after Phase II cancer jab trial misses primary endpoint
Despite this setback, Transgene plans to explore the potential benefits of the vaccine in specific patient populations.
Read the original article

Tags:

Previous Article

Bayer applies for EU approval of menopause drug elinzanetant

Next Article

GITEX GLOBAL 2024: Huawei launches a series of industrial digital and intelligen...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

GSK’s Ojjaara receives FDA approval for treating myelofibrosis patients with anaemia

GSK’s Ojjaara receives FDA approval for treating myelof...

Sep 21, 2023

Opinion: After 20 years in rehabilitation research, my young daughter’s traumatic brain injury transformed my mind and my career

Opinion: After 20 years in rehabilitation research, my ...

Jan 24, 2024

STAT+: If AI invents a new medicine, who gets the patent?

STAT+: If AI invents a new medicine, who gets the patent?

Jun 8, 2023